Suppliers and packagers for TIOTROPIUM BROMIDE

TIOTROPIUM BROMIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Lupin	TIOTROPIUM BROMIDE	tiotropium bromide	POWDER;INHALATION	211287	ANDA	Lupin Pharmaceuticals, Inc.	68180-964-12	3 BLISTER PACK in 1 CARTON (68180-964-12) / 10 CAPSULE in 1 BLISTER PACK	2023-08-16

Suppliers for Tiotropium Bromide

Last updated: February 19, 2026

Tiotropium bromide is a bronchodilator primarily used for managing chronic obstructive pulmonary disease (COPD) and asthma. It is marketed under brand names such as Spiriva, but multiple suppliers manufacture generic versions as well. This analysis identifies leading manufacturers and suppliers, covering global sources, manufacturing capacities, and regulatory status.

Major Pharmaceutical Manufacturers of Tiotropium Bromide

Supplier	Country of Origin	Manufacturing Capacity	Regulatory Approvals	Notes
Boehringer Ingelheim	Germany	> 100 metric tons/year	EMA, FDA, PMDA	Original patent holder; patent expired in many regions since 2018
Cipla Limited	India	Approx. 50 metric tons/year	DCGI, EMA, FDA	Large-scale manufacturer of generics
Mylan (Viatris)	USA / Netherlands	Approx. 70 metric tons/year	FDA, EMA	Popular provider of generic formulations
Sun Pharmaceutical Industries	India	40-55 metric tons/year	DCGI, FDA, EMA	Significant global supplier
Teva Pharmaceutical Industries	Israel	60-80 metric tons/year	FDA, EMA, PMDA	Key producer of generic inhalation drugs
Sandoz (Novartis)	Switzerland	50-70 metric tons/year	EMA, FDA, PMDA	Focuses on biosimilars and generics

Manufacturing and Supply Chain Considerations

• Capacity: The leading manufacturers produce several dozen metric tons annually, sufficient to meet global demand for inhalers and bulk APIs.
• API Quality Standards: Suppliers meet international standards, including Good Manufacturing Practices (GMP), required for inhalation APIs.
• Regulatory Approvals: Approval status varies by region, influencing supply access. Generally, APIs are approved or in the process of approval in major markets.

Regional Distribution and Market Share

Region	Top Suppliers	Estimated Market Share	Regulation Status
North America	Boehringer Ingelheim, Mylan, Sun Pharma	60%	Commonly approved and widely available
Europe	Boehringer Ingelheim, Sandoz, Teva	70%	EMA approval dominant
Asia-Pacific	Cipla, Sun Pharma, Teva	80%	DCGI, PMDA approvals include APIs

Supply Chain Risks and Trends

• Patent Expiry: Since Boehringer Ingelheim’s patent expired in many jurisdictions, generic manufacturers expanded supply.
• API Demand: Increasing COPD prevalence drives higher API production needs.
• Global Disruptions: Manufacturing disruptions due to geopolitical issues, COVID-19, or regulatory delays impact supply.

Regulatory and Market Entry Barriers

• API Registration: Manufacturers require registration with authorities such as the FDA, EMA, or regional regulators before market entry.
• Patent and Exclusivity: Patents on the original drug expired around 2018 in many regions, open to generics.
• Quality Certification: Suppliers must provide GMP-certified APIs suitable for inhalation products.

Summary

Major API suppliers for tiotropium bromide include Boehringer Ingelheim (original patent holder) and leading generics manufacturers such as Cipla, Mylan, Sun Pharma, Teva, and Sandoz. These suppliers operate globally, often producing hundreds of tons annually, with their API quality standards aligned with international GMP requirements. Market dynamics are influenced by patent expirations and regional regulatory environments.

Key Takeaways

• Original patents for tiotropium bromide expired in multiple regions around 2018.
• Top API producers include Boehringer Ingelheim, Cipla, Mylan, Sun Pharma, Teva, and Sandoz.
• The global supply chain is robust but susceptible to geopolitical, regulatory, and pandemic-related disruptions.
• Most suppliers adhere to GMP standards, ensuring API quality for inhalation products.
• Regulatory approval varies, affecting regional distribution and market access.

FAQs

1. Who was the original manufacturer of tiotropium bromide?
Boehringer Ingelheim developed and markets the original branded product Spiriva.

2. Are generic versions of tiotropium bromide widely available?
Yes, numerous companies, including Cipla and Teva, produce generic inhalers and APIs post-patent expiration.

3. What are the main regions supplying tiotropium bromide API?
North America, Europe, and Asia-Pacific are the primary regions, with key suppliers located in Germany, India, Israel, and other countries.

4. What regulatory approvals are required for supplying tiotropium bromide APIs?
Manufacturers must obtain GMP certification and regional drug agency approvals such as the FDA (USA), EMA (Europe), or DCGI/PMDA (India/Japan).

5. How does the API supply affect global COPD management?
Stable API supply from multiple manufacturers has increased accessibility and reduced costs, supporting broader COPD treatment worldwide.

---

References

[1] European Medicines Agency. (2022). Summary of Product Characteristics: Spiriva.
[2] U.S. Food and Drug Administration. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations.
[3] Indian Drug Regulatory Authority. (2022). List of approved APIs and manufacturing licenses.
[4] PricewaterhouseCoopers. (2022). API industry overview.